the new way how cancer can be managed
PRECISION MEDICINE
Precision Medicine offers the opportunity to consider cancer treatment in a radically different manner that may be much more effective.
Precision medicine, or also known as personalized medicine, is an approach that helps the doctors to understand a person’s genetic makeup and select the suitable treatments that may be more effective for the patients.
Before precision medicine, when you are diagnosed with cancer, you usually will receive the same treatment as others with the same type and stage of cancer. However, it has been noted that certain treatments worked better for some people while ineffective in others.
Researchers have discovered that different responses of patients to the same treatment is due to the genetic differences in them that cause cancer to grow and spread.
Our Technologies
Liquid biopsy is a test done on a blood sample, to look for circulating tumour cells (CTC) or pieces of circulating tumour DNA (ctDNA) shed by cancer cells in the blood of a patient. Procedure is rather safe, simple, fast, and cost effective, which only involves the extraction of patients’ blood.
Next generation sequencing (NGS) is a new method in genome/ DNA sequencing, with improved accuracy and speed. NGS is used to examine and detect DNA mutations, copy number variations and gene fusions across the genome. In most cases, cancer usually involves mutations in multiple genes. Therefore, looking at single gene mutation is often insufficient for targeted therapy.
Clinical annotation of an entire gene panel with NGS allows assessment of multiple parameters concurrently, enabling highest effectiveness and efficacy in cancer treatments[3].
Polymerase Chain Reaction (PCR) is a technique used to amplify a specific piece of DNA or RNA from a sample. PCR can be used to detect certain chances in gene or chromosome. Fragment analysis is a genetic marker analysis which rely on the detection of the changes in the length of a specific DNA sequence to indicate the presence of absence of a genetic marker.
Multiplex Ligation-dependent Probe Amplification (MLPA) is a multiplex PCR method detecting abnormal copy numbers of specific genes, including small intragenic rearrangements for up to 50 different genomic DNA or RNA sequences. MLPA is a very important technique in the assessment of hereditary diseases including cancers.
It is especially indicated whenever large deletions or duplications are described for a gene[5].
In ONCODE, all the pipelines are fully automated in order to minimise human, instrumentation or technical errors as well as reducing accidents and risks. In order to ensure highest accuracy and minimization of instrumentation errors, ONCODE workflows follow the following practices
Our Technologies
Liquid biopsy is a test done on a blood sample, to look for circulating tumour cells (CTC) or pieces of circulating tumour DNA (ctDNA) shed by cancer cells in the blood of a patient. Procedure is rather safe, simple, fast, and cost effective, which only involves the extraction of patients’ blood.
Next generation sequencing (NGS) is a new method in genome/ DNA sequencing, with improved accuracy and speed. NGS is used to examine and detect DNA mutations, copy number variations and gene fusions across the genome. In most cases, cancer usually involves mutations in multiple genes. Therefore, looking at single gene mutation is often insufficient for targeted therapy.
Clinical annotation of an entire gene panel with NGS allows assessment of multiple parameters concurrently, enabling highest effectiveness and efficacy in cancer treatments[3].
Polymerase Chain Reaction (PCR) is a technique used to amplify a specific piece of DNA or RNA from a sample. PCR can be used to detect certain chances in gene or chromosome. Fragment analysis is a genetic marker analysis which rely on the detection of the changes in the length of a specific DNA sequence to indicate the presence of absence of a genetic marker.
Multiplex Ligation-dependent Probe Amplification (MLPA) is a multiplex PCR method detecting abnormal copy numbers of specific genes, including small intragenic rearrangements for up to 50 different genomic DNA or RNA sequences. MLPA is a very important technique in the assessment of hereditary diseases including cancers.
It is especially indicated whenever large deletions or duplications are described for a gene[5].
In ONCODE, all the pipelines are fully automated in order to minimise human, instrumentation or technical errors as well as reducing accidents and risks. In order to ensure highest accuracy and minimization of instrumentation errors, ONCODE workflows follow the following practices
Our Technologies
Liquid biopsy is a test done on a blood sample, to look for circulating tumour cells (CTC) or pieces of circulating tumour DNA (ctDNA) shed by cancer cells in the blood of a patient. Procedure is rather safe, simple, fast, and cost effective, which only involves the extraction of patients’ blood.
Next generation sequencing (NGS) is a new method in genome/ DNA sequencing, with improved accuracy and speed. NGS is used to examine and detect DNA mutations, copy number variations and gene fusions across the genome. In most cases, cancer usually involves mutations in multiple genes. Therefore, looking at single gene mutation is often insufficient for targeted therapy.
Clinical annotation of an entire gene panel with NGS allows assessment of multiple parameters concurrently, enabling highest effectiveness and efficacy in cancer treatments[3].
Polymerase Chain Reaction (PCR) is a technique used to amplify a specific piece of DNA or RNA from a sample. PCR can be used to detect certain chances in gene or chromosome. Fragment analysis is a genetic marker analysis which rely on the detection of the changes in the length of a specific DNA sequence to indicate the presence of absence of a genetic marker.
Multiplex Ligation-dependent Probe Amplification (MLPA) is a multiplex PCR method detecting abnormal copy numbers of specific genes, including small intragenic rearrangements for up to 50 different genomic DNA or RNA sequences. MLPA is a very important technique in the assessment of hereditary diseases including cancers.
It is especially indicated whenever large deletions or duplications are described for a gene[5].
In ONCODE, all the pipelines are fully automated in order to minimise human, instrumentation or technical errors as well as reducing accidents and risks. In order to ensure highest accuracy and minimization of instrumentation errors, ONCODE workflows follow the following practices
